Catalyst Pharmaceuticals, Inc. appointed Dr. Daniel Curran to its Board of Directors. Dr. Curran brings over 25 years of experience in the pharmaceutical industry, including roles at Takeda Pharmaceutical Company and Timberlyne Therapeutics. His expertise in rare diseases and business development will support Catalyst’s growth strategy. Dr. Curran holds an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from The Wharton School. Catalyst Pharmaceuticals is focused on developing innovative therapies for rare diseases, prioritizing patient care and accessibility. The company was recognized for its success on the Forbes 2025 list and the 2024 Deloitte Technology Fast 500™ list.

Read more at GlobeNewswire: Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its